0.94
+0.0872(+10.29%)
Currency In USD
| Previous Close | 0.85 |
| Open | 0.82 |
| Day High | 1 |
| Day Low | 0.81 |
| 52-Week High | 2.74 |
| 52-Week Low | 0.36 |
| Volume | 3M |
| Average Volume | 2.35M |
| Market Cap | 112.16M |
| PE | -0.79 |
| EPS | -1.19 |
| Moving Average 50 Days | 0.65 |
| Moving Average 200 Days | 0.83 |
| Change | 0.09 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $44.78 as of June 01, 2025 at a share price of $0.935. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $318.03 as of June 01, 2025 at a share price of $0.935.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus
GlobeNewswire Inc.
May 27, 2025 11:01 AM GMT
CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal antibody or vaccine with placebo-controlled clini
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
GlobeNewswire Inc.
May 23, 2025 11:01 AM GMT
WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Pract
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
GlobeNewswire Inc.
May 21, 2025 1:30 PM GMT
FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally aligns with recent Invivyd Citizen Petition requests